Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066196 · ClinicalTrials.gov registry record · Phase 2
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
A Phase 2 study of Melanoma and Malignant Metastatic Melanoma, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT00066196 is a Phase 2 study of Melanoma and Malignant Metastatic Melanoma that has completed, run by MedImmune. The registered enrollment target is 110 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00066196, a Phase 2 study of Melanoma and Malignant Metastatic Melanoma, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. * To determine the safety of MEDI-522 ± DTIC in this patient population.
Conditions Studied
Interventions
- BIOLOGICAL MEDI--522
- BIOLOGICAL Integrin + Dacarbazine
Study Locations (20)
California
- Pacific Shores Medical Group - Long Beach
- Saint Francis Memorial Hospital - San Francisco
- Cancer Institute Medical Group - Santa Monica
- Medical Group of North County - Vista
Indiana
- Indiana Oncology Hematology Consultants - Indianapolis
- Indiana University Medical Center - Indianapolis
Missouri
- Kansas City Oncology & Hematology Group - Kansas City
- The Melanoma Center of St. Louis - St Louis
New York
- HemOnc Care, P.C. - Brooklyn
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- UNC-Chapel Hill - Chapel Hill
- Blumenthal Cancer Center - Charlotte
Arizona
- Mayo Clinic Arizona - Scottsdale
Connecticut
- Yale University School of Medicine - New Haven
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2003-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066196
The ClinicalTrials.gov registry entry for NCT00066196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (84% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which MEDI--522 is the first listed.
NCT00066196 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Indiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT00066196 about?
NCT00066196 is a clinical study titled "Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma". The primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. * To determine the safety of MEDI-522 ± DTIC in this patient population.
What is the current status of trial NCT00066196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2003-08. Estimated completion is 2007-06.
What conditions does trial NCT00066196 study?
This clinical trial studies the following conditions: Melanoma, Malignant Metastatic Melanoma.
What interventions are being tested in trial NCT00066196?
The interventions under investigation include: MEDI--522 (BIOLOGICAL), Integrin + Dacarbazine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00066196?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00066196 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.